App-Quantinova.ai

EFFECT OF BIOLOGIC AGENTS ON LIPIDS AND CARDIOVASCULAR RISK IN RHEUMATOID ARTHRITIS PATIENTS

D. A. Pappas - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Inflammatory Arthritis

Tocilizumab

INTERLEUKIN 6 AND VASCULAR DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS

J. J. Alegre-Sancho - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Interstitial lung disease

Interleukin

FRACTURE HEALING OF DISTAL RADIUS FRACTURES ASSESSED BY HIGH-RESOLUTION PERIPHERAL QUANTITATIVE COMPUTED TOMOGRAPHY, BONE STRENGTH ANALYSIS AND BIOMARKERS

J. de Jong - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

N/A

F. Van Den Bosch - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Peripheral spondyloarthritis

Adalimumab

INDEPENDENT RISK FACTORS FOR CARDIOVASCULAR EVENTS IN MALE PATIENTS WITH GOUT: RESULTS OF THE 7-YEAR PROSPECTIVE FOLLOW-UP STUDY

M. S. Eliseev - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Chronic kidney disease

Allopurinol

EFFECTS OF PHYSICAL ACTIVITY ON INFLAMMATION, SKELETAL MUSCLE STRENGTH/FUNCTION (SARCOPENIA) AND FAT INFILTRATION (SARCOPENIC OBESITY) IN OLDER ADULTS WITH KNEE OSTEOARTHRITIS: A RANDOMIZED CONTROLLED TRIAL

S. Abou-Raya - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Knee osteoarthritis

N/A

IDENTIFICATION OF OSTEOARTHRITIS PATIENTS WITH CHRONIC TISSUE INFLAMMATION WHOM MAY BENEFIT FROM ANTI-INFLAMMATORY TREATMENT

A. S. Siebuhr - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Osteoarthritis

N/A

EVALUATION OF VARIOUS ENDOTHELIAL BIOMARKERS AND T HELPER-17 CYTOKINES IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER

I. Sari - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Familial Mediterranean fever

Thrombomodulin alfa

PERIPHERAL ARTERY DISEASE IN PSORIATIC ARTHRITIS: OVERLOOKED?

A. Abou-Raya - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Peripheral artery disease

Fibrinogen (IV)

ANTI-TNF THERAPY INDUCES POSITIVE CHANGES IN THE LIPOPROTEIN PROFILE OF RA PATIENTES. RESULTS OF A PROSPECTIVE STUDY

J. Calvo Alen - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

BENEFICIAL EFFECT OF ANTI-TNF THERAPY IN THE LIPOPROTEIN ATHEROGENIC RISK PROFILE IN COMPARISON WITH DMARD STANDARD THERAPY IN RA PATIENTS

J. Calvo Alen - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Methotrexate

RHEUMATOID ARTHRITIS (RA) PATIENTS PRESENT RELEVANT AND DIVERSE ALTERATIONS IN LIPID AND LIPOPROTEIN METABOLISM ASSOCIATED TO CARDIOVASCULAR (CV) RISK: PRELIMINARY RESULTS

J. Calvo Alen - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

SARILUMAB, A SUBCUTANEOUSLY-ADMINISTERED, FULLY-HUMAN MONOCLONAL ANTIBODY INHIBITOR OF THE IL-6 RECEPTOR: RELATIONSHIP BETWEEN EULAR RESPONSES AND CHANGE FROM BASELINE OF SELECTED CLINICAL PARAMETERS

M. C. Genovese - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Infant Respiratory Distress Syndrome

Sarilumab

SARILUMAB, A FULLY HUMAN MAB AGAINST IL-6R ALPHA, SUBCUTANEOUSLY-ADMINISTERED SHOWS SIGNIFICANT IMPROVEMENT IN RA PATIENTS AS EARLY AS 2 WEEKS: A TIME TO EVENT ANALYSIS FOR ACR50 AND EULAR GOOD RESPONSE

R. Fleischmann - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Sarilumab

THE INFLUENCE OF VARIATION IN C-REACTIVE PROTEIN VALUES ON THE DAS28 SCORE

R. Asmussen - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

HEPCIDIN, INTERLEUKIN-6 AND ANEMIA OF CHRONIC INFLAMMATION IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

C. C. Mok - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

ILS-969

HYPOVITAMINOSIS D AND THE METABOLIC SYNDROME IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

C. C. Mok - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Glucocorticoid

MICROVASCULAR FINDINGS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS - ASSESSED BY FUNDUS PHOTOGRAPHY AND FLUORESCENT ANGIOGRAPHY

J. H. Lee - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

ARE THERE DIFFERENCES IN BIOMARKERS OF CARTILAGE AND BONE TURNOVER BETWEEN PATIENTS WITH FAMILIAL VERSUS SPORADIC EARLY SPONDILOARTHRITIS?

R. Almodovar - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

Ophthalmology (OP)

Inflammatory bowel disease

N/A

SARILUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: RESULTS OF A PHASE 2, RANDOMIZED. DOUBLE-BLIND, PLACEBO-CONTROLLED, INTERNATIONAL STUDY (ALIGN)

J. Sieper - European League Against Rheumatism (EULAR) , 2012

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Ankylosing spondylitis

Sarilumab

Filters

1408 Abstracts